Effect of Recombinant Human Erythropoietin Therapy on Serum Erythropoietin Levels in Anemic CKD Patients in Baghdad City

Mohanad Yasir Al-Radeef^1, , Sajida Hussein Ismail² and Ali Abdul-Majid Dyab Allawi³

¹Department of Clinical Pharmacy, College of Pharmacy, Baghdad University, Iraq

²Department of Pharmacology and Toxicology, College of Pharmacy, Baghdad University, Iraq

³Department of Medicine, College of Medicine, Baghdad University, Iraq

Cite this paper:
Mohanad Yasir Al-Radeef, Sajida Hussein Ismail and Ali Abdul-Majid Dyab Allawi. Effect of Recombinant Human Erythropoietin Therapy on Serum Erythropoietin Levels in Anemic CKD Patients in Baghdad City. American Journal of Pharmacological Sciences. 2016; 4(4):46-50. doi: 10.12691/ajps-4-4-1

Abstract

Anemia is a common complication associated with chronic kidney disease (CKD). It develops early in the course of the disease increasing its frequency with the reduction in renal function. Methoxy polyethylene glycol-epoetin beta (MPGE-β) is a chemically synthesized recombinant human erythropoietin (rHuEPO) with a much longer half-life than endogenous erythropoietin (EPO). This study aimed to determine the influence of rHuEPO therapy on serum EPO levels in anemic CKD patients on maintenance hemodialysis. Seventy patients with CKD on maintenance hemodialysis receiving MPGE-β and twenty healthy subjects without medical illnesses were enrolled in this case-control prospective study. Patients had significantly lower serum EPO levels as compared to control healthy group because of relative EPO deficiency in renal anemic patients. Moreover, a significant rHuEPO dose adjustment was done during the first three months which results in a significant elevation in serum EPO levels in patients during the study. Relative EPO deficiency is common in CKD patients and the administration of rHuEPO usually leads to a significant elevation in serum EPO levels in these patients.

Keywords:
chronic kidney disease serum erythropoietin anemia rHuEPO

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Shiba N and Shimokawa H. “Chronic kidney disease and heart failure-Bidirectional close link and common therapeutic goal”. J. Cardiol., 2011; 57(1): 8-17.
[2]	El-Gohary IE, Abedl-Karim A, and Hashad DI. “Serum chemerin level: does it have a role in progression of diabetic nephropathy”. Am. J. Intern. Med., 2016; 4(2-1): 13-17.
[3]	Ramaprabha P, Bhuvaneswari T, and Kumar RA. “Coagulation profiles an indicator of vascular haemostatic function in chronic renal failure patients who are on renal dialysis”. Sch. J. App. Med. Sci., 2014; 2(2B):592-595.
[4]	Aditya I, Goswami S, Ghosh B, and Chatterjee TK. “Prevalence of anemia in CKD patients of eastern India on maintained hemodialysis”. Int. J. Curr. Res. Chem. Pharma. Sci., 2014; 1(3): 20-28.
[5]	O'Mara NB. “Anemia in patients with chronic kidney disease. Diabetes Spectr., 2008; 21(1): 12-19.
[6]	Snively CS and Gutierrez C. “Chronic kidney disease: prevention and treatment of common complications”. Am. Fam. Physician, 2004; 70(10):1921-1928.
[7]	Ribeiro S, Costa E, Belo L, Reis F, and Santos- Silva A. Ch.16: “rhEPO for the treatment of erythropoietin resistant anemia in hemodialysis patients – risks and benefits”, In: “Hemodialysis”, Suzuki H (Ed.), InTech, Croatia, 2013; p: 291-314.
[8]	Stauffer ME. and Fan T. “Prevalence of anemia in chronic kidney disease in the United States”. PLoS ONE, 2014; 9(1): e84943.
[9]	Thomas R, Kanso A, and Sedor JR. “Chronic kidney disease and its complications”. Prim Care, 2008; 35(2): 329–vii.
[10]	Zeisberg M and Kalluri R. “Physiology of the renal interstitium”. Clin. J. Am. Soc. Nephrol., 2015; 10(10): 1831-1840.
[11]	Jorgensen E, Bindslev L, Ripa RS, and Kastrup J. “Epo ‘cytokine-doping’ of heart disease patients, will it work?” Eur. Heart J., 2006; 27(15): 1767-1768.
[12]	Jelkmann W. “Developments in the therapeutic use of erythropoiesis stimulating agents”. Br. J. Haematol., 2008; 141(3): 287-297.
[13]	El-Komy MH, Schmidt RL, Widness JA, and Veng-Pedersen P. “Differential pharmacokinetic analysis of in vivo erythropoietin receptor interaction with erythropoietin and continuous erythropoietin receptor activator in sheep”. Biopharm. Drug Dispos., 2011; 32(5): 276-288.
[14]	Frimat L, Mariat C, Landais P, Koné S, Commenges B, and Choukroun G. “Anaemia management with C.E.R.A. in routine clinical practice: OCEANE (Cohorte Mircera patients non-dialysés), a national, multicenter, longitudinal, observational prospective study, in patients with chronic kidney disease not on dialysis”. BMJ Open, 2013; 3(3): e001888.
[15]	Hayder ZS, Aziz JM, and Jaff MS. “Effect of dialysis on erythropoietin and some hematological parameters in patients with chronic renal failure”. Zanco J. Med. Sci., 2009; 13(2).
[16]	Rahman M, Haque M, Alam T, Amin N, Parveen H, Al Mahmuda N, and Abbas G. “Serum erythropoietin level in chronic kidney disease patients with anemia: A baseline study at Chittagong medical college, Chittagong, Bangladesh”. Am. J. Clin. Exp. Med., 2016; 4(2): 20-25.
[17]	Boubaker K, Mahfoudhi M, Battikh A, Bounemra A, Maktouf C, and Kheder A. “Higher endogenous erythropoietin levels in hemodialysis patients with hepatitis c virus infection and effect on anemia”. Open J. Nephrol., 2015; 5: 29-34.
[18]	Artunc F and Risler T. “Serum erythropoietin concentrations and responses to anaemia in patients with or without chronic kidney disease”. Nephrol. Dial. Transplant., 2007; 22: 2900-2908.
[19]	Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney int., Suppl. 2012; 2: 299-310.
[20]	Provatopoulou ST and Ziroyiannis PN “Clinical use of erythropoietin in chronic kidney disease: outcomes and future prospects”. Hippokratia, 2011; 15(2): 109-115.
[21]	Lundby C and Olsen NV. “Effects of recombinant human erythropoietin in normal humans”. J. Physiol., 2011; 589(Pt 6): 1265-1271.